Gleevec remains effective in advanced GIST, with median overall survival of 75.3 months and significant long-term survival rates. Factors like female sex, gastric tumor location, smaller tumors, and ...

In 2001, a Time Magazine cover story touted Novartis’ targeted leukemia treatment Gleevec (imatinib) as a new kind of “ammunition in the war against cancer.” Along with a picture of the Gleevec pills, ...

For most of the 20th century, doctors treated cancer by hitting it with everything they had. Radical surgery, high-dose radiation, brutal chemotherapy. Even when it worked, the collateral damage was ...

Gleevec and Mektovi combination therapy demonstrated significant clinical benefits in advanced GIST, with a 69% objective response rate and prolonged survival outcomes. The 10-year follow-up of the ...

June 14, 2006 — Two new drugs overcome the resistance that can develop to the first-line-therapy imatinib ( Gleevec, Novartis) in chronic myeloid leukemia (CML), and results from phase 1 clinical ...

CHICAGO (Reuters) - An altered version of the cancer drug Gleevec could form the basis of a new class of drugs that block the development of brain-damaging plaques in Alzheimer's disease, U.S.

Suboptimal response or treatment failure to standard-dose imatinib are relevant problems in chronic-phase chronic myeloid leukemia patients. Insufficient adherence is one of the main causes of ...